For example, vemurafenib, which targets mutant BRAF, can lead to dedifferentiation in melanomas, making them more susceptible to ferroptosis, as evidenced by significant changes in lipid composition, including an increase in polyunsaturated fatty acids (PUFAs) [48]. The gene discussed is BRAF; the disease is melanoma.